US Patent

US11072614 — Polymorphs of sepiapterin and salts thereof

Method of Use · Assigned to PTC Therapeutics MP Inc · Expires 2038-04-16 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms of sepiapterin, including free base polymorphs and salts, and methods for preparing them.

USPTO Abstract

Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4251 — Sephience
U-4251 — Sephience

Patent Metadata

Patent number
US11072614
Jurisdiction
US
Classification
Method of Use
Expires
2038-04-16
Drug substance claim
Yes
Drug product claim
No
Assignee
PTC Therapeutics MP Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.